{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:02:29Z","timestamp":1760385749989},"reference-count":9,"publisher":"Copernicus GmbH","issue":"5","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Bone Joint Infect."],"abstract":"<jats:p>Abstract. We report a case of an infected massive endoprosthetic replacement treated successfully with 2 stage surgery and off-label dalbavancin. Dalbavancin was used due to a limited number of antimicrobial options that could be administered safely in an outpatient setting and to avoid the need for daily dosing.\n                    <\/jats:p>","DOI":"10.7150\/jbji.37980","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T10:29:17Z","timestamp":1572344957000},"page":"234-237","source":"Crossref","is-referenced-by-count":7,"title":["Dalbavancin to Treat Infected Massive Endoprostheses: A Case Report and Cost Comparison Analysis"],"prefix":"10.5194","volume":"4","author":[{"given":"Tariq","family":"Azamgarhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3145","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Osmon DR, Berbari EF, Berendt AR. et al. Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2013;56:e1\u2013e25.","DOI":"10.1093\/cid\/cis803"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Chapman ALN, Seaton AR, Cooper AM. et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. Journal of Antimicrobial Chemotherapy. 2012;67(5):1053\u2013106.","DOI":"10.1093\/jac\/dks003"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Streit JM, Sader HS, Fritsche TR. et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis. 2005;53(4):307\u201310.","DOI":"10.1016\/j.diagmicrobio.2005.03.004"},{"key":"ref4","unstructured":"Medicines.org.uk, Xydalba 500 mg powder for concentrate for solution for infusion. Electronic Medicines Compendium, 24 January 2019. https:\/\/www.medicines.org.uk\/emc\/product\/2270\/smpc."},{"key":"ref5","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL. et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;8(2):171\u2013184. [PMC free article]"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Almangour TA, Perry GK, Terriff CM. et al. Dalbavancin for the management of gram positive osteomyelitis: effectiveness and potential utility. Diagn Microbiol Infect Dis. 2019;93:213\u20138.","DOI":"10.1016\/j.diagmicrobio.2018.10.007"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Dunne MW, Puttagunta S, Sprenger CR. et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u20131855. [PMC free article]","DOI":"10.1128\/AAC.04550-14"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Dunne MW, Talbot GH, Boucher HW. et al. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016;39(2):147\u2013157. [PMC free article]","DOI":"10.1007\/s40264-015-0374-9"},{"key":"ref9","unstructured":"Li HK, Rombach I, Zambellas R. et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380:425\u201336. [PMC free article]"}],"container-title":["Journal of Bone and Joint Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jbji.copernicus.org\/articles\/4\/234\/2019\/jbji-4-234-2019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T09:31:04Z","timestamp":1596533464000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbji.copernicus.org\/articles\/4\/234\/2019\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.7150\/jbji.37980","relation":{},"ISSN":["2206-3552"],"issn-type":[{"value":"2206-3552","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}